ABSTRACT: The molecular basis for high resistance to clinical inhibitors of HIV-1 protease (PR) was examined for the variant designated PRP51 that was selected for resistance to darunavir (DRV). High resolution crystal structures of PRP51 with the active site D25N mutation revealed a ligand-free form and an inhibitor-bound form showing a unique binding site and orientation for DRV. This inactivating mutation is known to increase the dimer dissociation constant and decrease DRV affinity of PR. The PRP51‑D25N dimers were in the open conformation with widely separated flaps, as reported for other highly resistant variants. PRP51‑D25N dimer bound two DRV molecules and showed larger separation of 8.7 Å between the closest atoms of the two flaps ...
ABSTRACT 32 Dimerization of HIV protease is essential for the acquisition of protease’s proteolytic ...
HIV affects the lives of about 37 million patients worldwideincluding around one million Americans. ...
Drug resistance continues to be a growing global problem. The efficacy of small molecule inhibitors ...
The molecular basis for high resistance to clinical inhibitors of HIV-1 protease (PR) was examined f...
The molecular basis for high resistance to clinical inhibitors of HIV-1 protease (PR) was examined f...
The molecular basis for high resistance to clinical inhibitors of HIV-1 protease (PR) was examined f...
The molecular basis for high resistance to clinical inhibitors of HIV-1 protease (PR) was examined f...
HIV-1 protease is one of the prime targets of agents used in antiretroviral therapy against HIV. How...
HIV-1 protease is one of the prime targets of agents used in antiretroviral therapy against HIV. How...
We report structural analysis of HIV protease variant PRS17 which was rationally selected by machine...
AbstractHIV-1 protease (PR) is a 99 amino acid protein responsible for proteolytic processing of the...
Darunavir is the most recently approved human immunodeficiency virus (HIV) protease (PR) inhibitor (...
HIV-1 protease (PR) and its mutants are important antiviral drug targets. The PR flap region is crit...
ABSTRACT: HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively...
HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively used in t...
ABSTRACT 32 Dimerization of HIV protease is essential for the acquisition of protease’s proteolytic ...
HIV affects the lives of about 37 million patients worldwideincluding around one million Americans. ...
Drug resistance continues to be a growing global problem. The efficacy of small molecule inhibitors ...
The molecular basis for high resistance to clinical inhibitors of HIV-1 protease (PR) was examined f...
The molecular basis for high resistance to clinical inhibitors of HIV-1 protease (PR) was examined f...
The molecular basis for high resistance to clinical inhibitors of HIV-1 protease (PR) was examined f...
The molecular basis for high resistance to clinical inhibitors of HIV-1 protease (PR) was examined f...
HIV-1 protease is one of the prime targets of agents used in antiretroviral therapy against HIV. How...
HIV-1 protease is one of the prime targets of agents used in antiretroviral therapy against HIV. How...
We report structural analysis of HIV protease variant PRS17 which was rationally selected by machine...
AbstractHIV-1 protease (PR) is a 99 amino acid protein responsible for proteolytic processing of the...
Darunavir is the most recently approved human immunodeficiency virus (HIV) protease (PR) inhibitor (...
HIV-1 protease (PR) and its mutants are important antiviral drug targets. The PR flap region is crit...
ABSTRACT: HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively...
HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively used in t...
ABSTRACT 32 Dimerization of HIV protease is essential for the acquisition of protease’s proteolytic ...
HIV affects the lives of about 37 million patients worldwideincluding around one million Americans. ...
Drug resistance continues to be a growing global problem. The efficacy of small molecule inhibitors ...